Could Ebglyss challenge Dupixent in younger children? Almirall clears a crucial EMA filing hurdle
Almirall’s Ebglyss paediatric filing enters EMA review, opening a potential path into Europe’s childhood atopic dermatitis market.
Pharma & Biotech
Pharma & Biotech
Can Almirall turn dermatology momentum into a stronger long-term innovation engine?
Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.
Pharma & Biotech
Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?
Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.